Q4 2025 Earnings Call February 24, 2026 10:00 AM ESTCompany ParticipantsChris BrandonMichael Miles - Chairman of the Board ...

Q4 2025 Earnings Call February 24, 2026 4:30 PM ESTCompany ParticipantsByron Jeffers - VP, Treasurer & Head of ...

Delivered strong full year 2025 resultsCompleted Initial Public OfferingIntroduced full year 2026 guidanceFourth quarter net sales of $7.8 billion, an increase of 14.8%Fourth quarter net income of ...

C3.ai, Inc. ("C3 AI," "C3," or the "Company") (NYSE: AI), the Enterprise AI application software company, today announced ...

A new study reveals that the next generation of blockchain defenses will not rely on fixed rules alone but on adaptive, learning-based systems capable of evolving alongside intelligent adversaries.

Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the ...

CrossLink IGNITE Program -- Incentive initiative launched July 2025 and expanded, credited with accelerating ZYNRELEF ...

Daily biometrics, smart scales and AI companions are quietly rewriting the rules of aging.

Top-Line Data from Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 - - Raised Proceeds of $200 Million in ...

Delivered strong full year 2025 resultsCompleted Initial Public OfferingIntroduced full year 2026 guidanceFourth quarter net sales of $7.8 billion, an increase of 14.8%Fourth quarter net income of $18 ...

Market valued at $1.45B in 2024 grows at 10.4% CAGR driven by biocompatible hemostatic solutions in surgical and trauma ...

Full-year 2025 net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® (pegcetacoplan) full year 2025 net product revenue of ...